April 22nd 2024
Nogapendekin alfa-inbakicept is now approved for the treatment of patients with BCG-unresponsive non-muscle invasive bladder cancer.
Matthew D. Galsky, MD, on Key Takeaways From 2021 ASCO Annual Meeting in Bladder Cancer
June 9th 2021CancerNetwork® sat down with Matthew D. Galsky, MD, at the 2021 ASCO Annual Meeting to discuss his thoughts on research he believes has the greatest potential to impact standard of care treatment of bladder cancer.
Blue Light Cystoscopy May Help to Identify Bladder Cancer Recurrence Post-BCG
December 4th 2020“Providers should consider using BLC for surveillance of high-risk NMIBC patients undergoing BCG as it could change clinical management by identifying patients who are BCG unresponsive and eligible for alternative therapy and clinical trials,” said Meera Chappidi, MD.